Our results support the latest reports as we did not see any increase in TGF B or IL 11 mRNA or protein expression following stimulation with Th2 cytokines. Similarly, Th1 cyto kines had no effect on eosinophil derived TGF B expression. In fact, IFN was previously shown to inhibit TGF B production in human airway epithelial cells which is in consistence with our findings. The enhancement etc of eosinophil derived pro fibrotic cytokine release upon IL 17 cytokines stimulation was only significant in eosinophils isolated from asthmatic individuals. Although there was a slight upregulation of TGF B and IL 11 expression in eosinophils isolated from healthy individuals upon IL 17 stimulation, this increase did not reach significance.
Peripheral blood eosino phils of asthmatic patients were shown to be primed compared to those of healthy subjects which may render them more susceptible to IL 17 effect. Our results suggest that IL 17 cytokines enhance pro fibrotic activity of activated, such as in the case of allergic and auto immune diseases, but not resting eosinophils. Furthermore, our data indicated that asthmatic eosinophils may express higher levels of IL 17R than those of healthy controls. IL 23 was shown to increase expression of IL 17RA and IL 17RC in eosinophils and hence this observed poten tial increase in IL 17R in asthmatic eosinophils could be due to increased serum IL 23 in those patients. Serum levels of IL 23 were shown to inversely correlate with level of pulmonary function of asthmatic patients in va rious reports.
This may indicate that, due to the expected increase in serum IL 23 with asthma severity, eosinophils isolated from mild and moderate asthmatic patients may express higher levels of IL 17 receptors than eosinophils of healthy controls but lower than those of severe asthmatic patients. Understanding the correlation between asthmatic patients IL 23 serum levels, the expres sion of IL 17R on peripheral blood eosinophils, and the severity of asthma requires further investigations. Eosinophils are known to produce IL 17 cytokines and IL 23 was shown to stimulate the expression of IL 17A cytokine. This may indicate that IL 23 could stimulate eosinophils release of pro fibrotic cytokines indirectly by triggering their release of IL 17A. This possibility, however, needs to be further investigated. Stimulating eosinophils with IL 17 cytokines at a physiologically relevant concentration resulted in an increase in TGF B and IL 11 production although not to a significant levels. While stimulating Carfilzomib eosinophils with either IL 17A or F alone did not enhance a significant increase in pro fibrotic cytokines, using a combination of both cytokines did indicating an additive effect.